EGFR Exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas Version 2 tissue testing but has durable intracranial and extracranial response to osimertinib
AffiliationLung Unit, The Royal Marsden Hospital, Chelsea, London, United Kingdom; Institute of Cancer Research, Sutton, London,
MetadataShow full item record
CitationColeman N, Woolf D, Welsh L, McDonald F, MacMahon S, Yousaf N, et al. EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. J Thorac Oncol. 2020;15(10):e162-e5.
JournalJournal of Thoracic Oncology